



Thank you for your interest in ICLIO Visiting Experts, a one-day, personalized learning initiative conducted by the Institute for Clinical Immuno-Oncology (ICLIO), an Institute of the Association.

Held onsite at your institution, the program will be conducted by the ICLIO Visiting Experts team. This four-member faculty team will provide a tailored curriculum on the nuances and complexities of immuno-oncology.

In order to be considered for this opportunity, your institution must meet all of the following criteria:

- Be a current ACCC Cancer Program Member in good standing
- Have already established—or are in the early stages of implementing—an immuno-oncology program, and be willing to discuss your practices with ACCC and ICLIO
- Identify and assign a champion to interact and coordinate with the ICLIO project team.
- Have treated at least 50 or more patients with immunotherapy in the last 12 months
- Have plans to expand your immuno-oncology program over the next 2 years
- Complete this learning lab application form
- Enlist commitment of 5 or more key oncology professionals who will participate in the program:
 - Physician(s) (oncology, radiation oncology, surgical, internal etc.)
 - Nurse(s)
 - Pharmacist(s)
 - Social worker(s)
 - Financial counselor(s)
 - Administrator(s)
 - Other (e.g. nurse navigator)
- Approval for ACCC and ICLIO to publish key findings and outcomes from your workshop on their respective websites, as well as in white papers, social media posts, webinars, blogs, newsletters, and live education conferences.

To be considered for this opportunity, please submit this application by December 21, 2016 to Brissan Guardado via email at bguardado@acc-cancer.org.

ACCC Cancer Program Name:

Name of Individual(s) Involved in Completing the Application:

What is Your Role on the Multidisciplinary Cancer Care Team?

Cancer program administrator

Medical oncologist

Pharmacist

Cancer registry manager/coordinator

Other: _____

Information about Your Immuno-Oncology Program:

1) On average, how many patients does your program treat with immuno-oncologic agents per year (Checkpoint inhibitors [anti-pd1s, anti CTLA-4s]/vaccines/other immunotherapies used to treat patients with cancer)?

0 – 25

25 – 50

50 – 75

75 – 100

>100

2) Of the immunotherapy drugs prescribed at your program, how many cases per year are prescribed for each of the following tumor types?

	0 - 25	25 - 50	50 - 75	75 - 100	>100
Lung	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Metastatic Melanoma	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Renal Cell Carcinoma	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Bladder	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Other(specify)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

3) On a scale of 1 to 5 (with 1 being not operational and 5 being fully operational) please rate the immuno-oncology program at your institution.

1	2	3	4	5
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

4) Please rate your staff's knowledge of the following clinical characteristics of immunoncology (I-O).

	No knowledge	Little knowledge	Don't know/Not sure	Somewhat knowledgeable	Very knowledgeable
I-O Indications (specific tumor types treated)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
I-O Mechanisms of Action	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Response Assessment to I-O Therapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
I-O Sequencing Considerations (1st line, 2nd line, 3rd line)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Use of I-O Monotherapy vs. Combination Therapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Management of immune-related Adverse Events (irAEs)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Use of I-O Biomarkers	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

5) Please rate the quality of the interactions and communications within your immunoncology multidisciplinary team (oncologist, pharmacist, nurse, administrator, other healthcare provider).

- Very Good
- Good
- Fair
- Poor
- Very Poor

6) Please indicate your level of agreement with the following statements:

	Strongly agree	Agree	Neither agree nor disagree	Disagree	Strongly disagree
Our program experiences coverage and reimbursement barriers to immuno-oncology agents	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Our program is able to handle pre-certifications or prior-authorizations for I-O use	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Our program takes advantage of patient assistance programs and foundations for patient financial support	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Our program has updated protocols and management pathways to account for patients treated with immuno-oncologic agents and immune-related Adverse Events (irAE)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Our program provides education in a timely manner regarding emerging I-O clinical information to the multidisciplinary team	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Our program is well-equipped and staffed to handle immune-related Adverse Events (irAE)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Our program facilitates tumor board and multidisciplinary team meetings to discuss indications for and potential benefits of immuno-oncology agents for specific patients	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

7) With regards to nurse care coordination for I-O patients, please rate your top three challenges. (Please assign 1-3 to the options below)

Nurse triage responsibilities (pre-screening of patients, review of medical records, etc.)	_____
Educating patients regarding immunotherapies and irAEs	_____
Patient care follow-up and interactions (tests, consultations, irAE monitoring, etc.)	_____
Coordinating with psychosocial services, and/or financial and business advisors	_____
Travel coordination for patients	_____
Managing patient expectations and treatment timelines	_____

8) Please share your programs top three challenges/concerns as you prepare to implement or improve your immuno-oncology program (e.g. Management of irAEs, Care Coordination, Coverage and Reimbursement, Practice Operation Issues, Medication Safety, Inventory):

1) _____

2) _____

3) _____

9) Please share any other key topics or concerns that you would like the ICLIO Visiting Experts faculty to include in your workshop.

- 10) Please provide the name, title, email, and phone number of the clinician/team member in your program who will serve as the “champion” for this program. (The Champion will play the key role in interacting and coordinating plans with the ICLIO project team.)

Thank you for your interest in participating in the **ICLIO Visiting Experts** program. You will be notified in January 2017 when a decision has been made.